Toft Group Completes Search for Vice President, Biotherapeutics Research & Development for Codexis, Inc. (NASDAQ: CDXS), in Redwood City, CA

Executive search firm Toft Group has placed Hicham Alaoui, Ph.D. as Vice President, Biotherapeutics Research & Development for Codexis, Inc. in Redwood City, CA.

Dr. Alaoui has more than 20 years of experience with drug discovery and development organizations. Most recently Dr. Alaoui served as Senior Vice President, Discovery Biology and co-head of Research at Symic Bio. Prior to Symic Bio, Dr. Alaoui worked at Genentech, ultimately leading a large in vitro pharmacology group dedicated to lead discovery and optimization for both biotherapeutic and small molecule programs. Prior to Genentech, he worked in R&D leadership positions at Stryker Biotech, VisEn Medical, Neogenesis Pharmaceuticals, and Shire BioChem.

Dr. Alaoui earned a Ph.D. in Microbiology and Immunology at McGill University, Montreal, Quebec, and an M.Sc. in Biochemistry from Pierre and Marie Curie Université, Paris.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.